Spirulina Supplementation and Infant Growth, Morbidity and Motor Development

NCT ID: NCT03523182

Last Updated: 2019-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

501 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-01

Study Completion Date

2018-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: In developing countries, micronutrient deficiency in infants is associated with growth faltering, morbidity, and delayed motor development. One of the potentially low-cost and sustainable solutions is to use locally producible food for the home fortification of complementary foods.

Objective: The objectives are to test the hypothesis that locally producible spirulina platensis supplementation would achieve the following: 1) increase infant physical growth; 2) reduce morbidity; and 3) improve motor development.

Design: 501 Zambian infants are randomly assigned into a control (CON) group or a spirulina (SP) group. Children in the CON group (n=250) receive a soya-maize-based porridge for 12 months, whereas those in the SP group (n=251) receive the same food but with the addition of spirulina. The change in infants' anthropometric status, morbidity, and motor development over 12 months are assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Micronutrient deficiency in the infancy is associated with growth faltering, morbidity, and delayed motor development, and is common in developing countries where the food available for infants has low micronutrient density.

A low-cost and sustainable way to address this problem is to utilize locally producible foods rich in multi-micronutrients as home supplements to complementary food. Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.

It contains a high percentage of protein, and is rich in multiple micronutrients know to support infant growth such as beta carotene, B vitamins, and minerals such as calcium, iron, magnesium, manganese, potassium, and zinc. The cost of producing spirulina is much lower than that of producing other comparably protein-rich foods, such as soya beans and beef, and therefore may potentially sustainably meet the nutritional demands of African infants.

Our objective is to assess the acceptability and effects of spirulina supplementation on growth, incidence of morbidity, and level of motor development in infants in Zambia. The testable hypothesis is that spirulina supplementation for 12 months would increase infant height, reduce the incidence of morbidity, and reduce time taken to achieve motor development milestones (ability to walk unassisted).

This study is conducted from April 2015 to April 2016 in the form of an open-labeled randomized control trial, and involves in a spirulina-fed treatment (SP) group and a control (CON) group.

501 Zambian infants are randomly assigned into a control (CON) group or a spirulina (SP) group. Children in the CON group (n=250) receive a soya-maize-based porridge for 12 months, whereas those in the SP group (n=251) receive the same food but with the addition of spirulina.

The change in infants' anthropometric status, morbidity, and motor development over 12 months are assessed.

Amendment: the study period has been extended by 4 months. Without no-intervention period, monthly supplementation was restarted in study are.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stunting Underweight Pneumonia, Pneumocystis Cough Malaria Fever Motor Delay

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spirulina (SP)

Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.

Group Type EXPERIMENTAL

Spirulina

Intervention Type DIETARY_SUPPLEMENT

Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.

Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.

We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend.

Control

Intervention Type DIETARY_SUPPLEMENT

Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.

Control (CON)

Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.

Group Type ACTIVE_COMPARATOR

Control

Intervention Type DIETARY_SUPPLEMENT

Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spirulina

Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.

Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.

We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend.

Intervention Type DIETARY_SUPPLEMENT

Control

Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All infants were eligible for the study if they are between 6 and 18 month of age

Exclusion Criteria

* Non-singleton birth infants were excluded
Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hitotsubashi University

OTHER

Sponsor Role collaborator

Alliance Forum Foundation

UNKNOWN

Sponsor Role collaborator

Programme Against Malnutrition

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kazuya Masuda, PhD

Role: PRINCIPAL_INVESTIGATOR

Hitotsubashi University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Programme Against Malnutrition

Mansa, Luapura, Zambia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Zambia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FWA00000338

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.